Teva Pharmaceutical Industries Limited (TEVJF)
| Previous close | 11.75 |
| Open | 11.75 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 11.75 - 11.75 |
| 52-week range | 7.03 - 15.87 |
| Volume | |
| Avg. volume | 1,908 |
| Market cap | 15.7B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | N/A |
- Business Wire
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva’s operations and value chain by 2045 and 100% renewable electricity across all Teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity building
- GlobeNewswire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva PharmaceuticalsThe high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AVIV, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO)
- Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under
